Introduction
============

Macromolecular prodrugs, especially polymer-drug conjugates, which were first proposed by Ringsdorf in the mid 1970s, are the foundation for new types of anti-cancer entities.[@b1-ijn-5-063] Soon after this, very promising antitumor activities (eg, due to the alteration of parent drug pharmacokinetics/pharmacodynamics) were demonstrated for these structures in preclinical and clinical study phases.[@b2-ijn-5-063] Conventionally, hydrophilic, linear and branched bio- or nonbiodegradable polymers such as natural polymers; the linear polymers of amidoamines, or N-(2-Hydroxypropyl) methacrylamide (HPMA)-copolymers have been utilized as carriers for anticancer agents. However, these polymers have shown some drawbacks, eg, unpredictable and uncontrollable pharmacokinetic/pharmacodynamic behaviors due to their inherently high polydispersity index which are due to the heterogeneous products formed.[@b3-ijn-5-063] Today, polymeric structures with very low polydispersity, eg dendrimers, are being preferred as carriers of antitumor drugs. Dendrimers are a series of polymeric architectures with different chemical and surface-related properties. In comparison to traditional polymers, dendrimers have been claimed to be superior due to their nanoscale (nanometer-sized polymers) architecture, narrow polydispersity index, and the large number of surface reactive/functional sites with the potentiality for bond formation with therapeutics.[@b4-ijn-5-063]

Yet, not all of the dendrimers are suitable in this respect; biocompatible properties like aqueous solubility, biodegradation, low cytotoxicity and nonimmunogenicity properties must be verified for them both *in vitro* and *in vivo*.[@b5-ijn-5-063] One variant of these macromolecular prodrugs that has been partially investigated is the dendrimer cisplatin conjugates.[@b6-ijn-5-063] Encouraging outcomes in the treatment of various kinds of cancer cells have been reported for these compounds.[@b7-ijn-5-063] However, one major problem associated with these drug conjugates is the toxicity of the dendrimers themselves. This toxicity is dependant upon the physico-chemical properties of the dendrimers.[@b5-ijn-5-063] Research and development of dendrimer-based antineoplastic prodrugs can be accelerated with the use of biologically safe dendrimers, as carriers for conventional anticancer drugs. This is especially pertinent for cancers with drug resistance eg, as a consequence of the reduction in drug uptake. Cisplatin, an anticancer drug (cis-diamminedichloroplatinum with a molecular weight of 300.04 Da) used extensively in the treatment of many cancers such as ovarian, head, neck, testicular, and small cell lung carcinoma was chosen as a model drug to study its physicochemical interactions with the dendrimers.[@b8-ijn-5-063] The disadvantages of low aqueous solubility, high protein binding that reduce drug potencies, together with the non-specific or systemic toxicity (eg, nephrotoxicity) and both inherent/or acquired resisitences in many types of treatments have been reported for platinum-derived drugs.[@b9-ijn-5-063],[@b10-ijn-5-063] Thus, our objective for studying these dendrimer-Pt conjugates was to increase the anticancer potency of cisplatin by increasing its water solubility, decreasing its protein binding, and also reduction its nephrotoxicity with a view to their clinical use. It is postulated that these advantages could be gained by displacing the transient, easily alterable chemical agents of cis-platin (ie, chloride ions) with groups such as carboxylate ions on the dendrimer surfaces, so as to form more stable bonds (due to greater thermodynamic stability, steric effects, and ring stability of carboxylate ions versus the chloride ions) with cisplatin and prevent nonspecific and undesirable reactions with strong nucleophilic groups (eg, thiols present in plasma proteins or membrane walls of kidney cells) resulting from cisplatin's poor water-stability prior to reaching their sites of actions.[@b11-ijn-5-063]--[@b14-ijn-5-063] Increasing the stability of these bonds would preclude undesirable protein binding and systemic toxicities that are associated with cisplatin therapy.

Using citric acid in the synthesis of these dendrimers, it was hoped that the conjugates thus formed would be able to overcome the reduced uptake of cisplatin in cell lines with intrinsic and/or acquired resistances. It was hypothesized that this could be achieved by sequestering cisplatin (ie, masking via the linkage process) and supplying the cell's energy needs with the citric acid (a key component in the synthesis of adenosine triphosphate), utilized in the synthesis of the dendrimers. It was hoped that, dendrimers synthesized in this way can carry the drug into the cells without any intervention of the resistance mechanisms. So, two generations of anionic, water-soluble, linear-globular dendrimers G1 (MW\~1000 Da) and G2 (MW\~2000 Da), where poly ethylene glycol (PEG) is the core and citric acid is the periphery, were selected for the subsequent couplings with cisplatin.

These dendrimers had been synthesized before by Namazi and colleagues.[@b15-ijn-5-063],[@b16-ijn-5-063] and in our previous studies any *in vitro* cytotoxicity, immunogenicity, and hemotoxicity were not observed up to the concentration of 0.5 mg/mL (Alavidjeh and colleagues.unpublished data). First, In this study, surface conjugations and surface properties of the dendrimers (eg, size and zeta potential distribution) as a result of the reaction with cisplatin were examined using Fourier transform infrared (FT-IR) spectroscopy and dynamic light scattering (DLS ) technique. The reaction kinetics of cisplatin in the absence and presence of the dendrimers was investigated by measuring the chloride ions released using an ion selective electrode. The amount of drug loading on each of the conjugates was determined by atomic absorption spectroscopy (AAS). The *in vitro* release of cisplatin was examined in a two buffer media with two pHs of 7.4 and 5.4, simulating the conditions of plasma and secondary lysosomes, for 72 hours to estimate the stability and strength of the conjugates under those conditions. The *in vitro* cytotoxic potential of the conjugates was examined using sensitive cell lines HT1080, CT26 and a partially resistant cell line SKOV3. The hemolytic behavior of each of the conjugates was examined at different concentrations and a variety of durations to to assess the hemotoxicity of these compounds versus free cisplatin. Finally the mechanisms of cell death induced by the conjugates and free cisplatin, in two different concentrations, were studied by flow cytometry method as these mechanisms are considered important in the final outcome of cancer therapy.[@b17-ijn-5-063] In summary, the results of these studies would be able to assist in the primary screening of more potent macromolecular prodrugs with less systemic side effects.

Materials and methods
=====================

Materials
---------

The dendrimers (G1, \[1000 Da\] and G2, \[2000 Da\]) had previously been prepared by the method of Namazi and colleagues.[@b15-ijn-5-063],[@b16-ijn-5-063] Cisplatin (II) (MW 300.4 Da) and methyl thiazolyl tetrazolium (MTT) powder were purchased from Sigma- Aldrich, (Sigma-Aldrich Inc, St. Louis, MO, USA). Dialysis bag (molecular weight cut-off, 100--500 Da) was purchased from Spectrumlabs (Spectra/por^®^, Rancho Dominguez, CA, USA). Cell lines HT1080 (Human fibrosarcoma, ATCC, CCL-121), SKOV3 (Human ovarian, NCBI code; C209), CT26 (fibroblast, NCBI code; C532) were purchased from The Pasteur Institiute (Tehran, Iran), and AnnexinV-PI kit was obtained from Roche (Roche company, AnnexinV-FLUOS^®^, Basel, Switzerland).

Preparation of the cisplatin derivatives
----------------------------------------

The dendrimers with carboxylate end groups were reacted with cisplatin in two different molar ratios ie, 1:2 and 1:3. Typically, 180 mg of cisplatin (6 × 10^−4^ mole) and the dendrimers, G1 (2--3 × 10^−4^ mole), G2 (2--3 × 10^−4^ mole), were dissolved in 120 mL and 60 mL of double deionized water (D.D.W) separately for each of the reactions. Each dendrimer solution was then partially neutralized using 0.01 M NaOH solution, to provide the nucleophilic carboxylate end groups, and then freeze-dried for subsequent reactions with cisplatin. The dendrimer solutions, in different molar ratios, were added dropwise to the cisplatin solution with constant mild stirring. The stirring was continued, in the dark, for 18 hours. At the end of the reaction the mixtures were transferred to a dialysis bag and dialyzed against D.D.W for 72 hours to separate the unreacted cisplatin from the formed conjugates. A sample from the filtrate was transferred to a TLC plate and tested for the absence of cisplatin as mentioned in the USPXXIV Pharmacopea (developer: acetone and 1M nitric acid (90:10); spray reagents: stannous chloride, hydrogen chloride, and potassium iodide). When no platinum release was observed after 72 hrs, the samples inside the dialysis bag were lyophilized and kept at −20 °C for further analyses. The schematic structural diagrams of the dendrimers, cisplatin, and the possible formed conjugates were depicted in [Figure 1](#f1-ijn-5-063){ref-type="fig"}.

Chloride release
----------------

In order to have a comparison between the kinetics of the reaction of cisplatin with or without the dendrimers in the reaction media, the rate of chloride release was measured from cisplatin in both the absence and presence of the dendrimers in D.D.W using an ion selective electrode (Metrohm^®^, Oberdorfstrasse, Switzerland).

Drug loading
------------

The drug loading range was determined by atomic absorption spectroscopy (AAS) method (SpectrAA240, Varian Inc, Palo Alto, CA, USA) for each of the derivatives in two different molar ratios.

Platinum release
----------------

The dendrimer-Pt conjugates (10 mg/mL) were each dissolved in two different Sorenson's buffers pH 7.4 and 5.4, to simulate the physiological media. The resultant samples were then dialyzed against the same buffers, at 37 °C for 72 hrs. After each time interval a sample was taken to determine the platinum content of the conjugates by the AAS method.

Size and zeta potential distribution
------------------------------------

Each of the dendrimers and conjugates (0.5 mg/mL) was checked for any changes in the size and zeta potential distribution before and after the reaction with the cisplatin by DLS technique (Malvern, Zetasizer Nano ZS, Worcestershire, UK) in D.D.W.

FT-IR studies
-------------

The spectral changes of the dendrimers were examined by Fourier transform infrared (FTIR) spectroscopy (Thermo-Nicolet, NEXUS 870, Waltham, MA, USA) before and after the conjugation. Through changes in the wavenumbers of the functional groups in the IR spectra, we were able to show the surface conjugation and clarify which groups were involved in the conjugation process.

*In vitro* toxicity assay
-------------------------

MTT assay is one the current techniques which is widely used for cell viability measurement. This assay is based on the reduction of MTT to formazan by viable cells.[@b18-ijn-5-063],[@b19-ijn-5-063] At the end of the incubation times (24, 48 hrs) with various concentrations of the conjugates (0.787, 1.575, 3.15, 6.3 μg/mL; equivalent to free cisplatin) and pristine cisplatin, the supernatants of the cells (HT1080, SKOV3, CT26) were removed. MTT solution was added to each well of the plates to give the final concentration of 0.5 mg/mL, and the cells were incubated for an additional 4 hours. Thereafter, the solutions were removed, and the dye was dissolved in 100 μl dimethyl sulfoxide; the plates were kept in a dark place for another one hour in order to be ready for spectrophotometric determination. The amount of absorption in each well; that is, the conversion of MTT to formazan by metabolically viable cells, was calculated by an automated microplate reader at 570 nm. The results were devided to the absorption of the untreated control culture and expressed as percentage of viable cells.

Hemolysis assay
---------------

Blood samples were taken from un-medicated volunteers (anti-coagulated samples). The final hematocrit fraction was obtained after centrifuging the whole blood at 1000 rpm for 5 min, and discarding the supernatant. The cells were then rinsed three times with cold phosphate buffered saline (PBS 5% v/v). The conjugates and free cisplatin were then dissolved in PBS and incubated and shaken at 37 °C and 50 rpm respectively for two hours with the blood sample mixtures, composed of 1:5 v/v conjugate solutions to blood to make the final, specified concentrations of the conjugates and cisplatin (1.575, 3.15, 6.3 μg/mL weight equivalent to free cisplatin). Following this the mixture was centrifuged at 1000 rpm for 5 min and the supernatants removed and analysed using a spectrophotometer at 413 nm. The results were then compared to the positive control (0.1% v/v Triton-X100 in PBS) which produces 100% hemolysis and negative control which contained only a mixture of blood and PBS as an indicator for the minimum hemoglobin release.[@b19-ijn-5-063],[@b20-ijn-5-063]

Apoptosis-necrosis assay
------------------------

Apoptotic and necrotic cells were identified by an AnnexinV-PI Staining Kit. Apoptosis and necrosis have been considered as the two different mechanisms of the cell death. By this technique, we are able to measure and differentiate between these two mechanisms.[@b19-ijn-5-063],[@b21-ijn-5-063] Following the incubation for 24 hours with two different concentrations of the G1+Pt, G2+Pt and free cisplatin (0.75 and 1.5 μg/mL, the weight equivalent to cisplatin) with the HT1080 Cells, and they were washed three times with PBS, trypsinized, and transferred to a new tube. Following this the cells were centrifuged at 200 × g for 5 minutes, stained using trypan blue and then counted using a hemocytometer, Approximately 10^6^ cells were analyzed for each flow cytometry run. The cells, both treated and untreated ones, were then incubated with the AnnexinV-PI (propidium iodide) reagent buffer for 15 minutes at room temperature. Following the incubation the samples were diluted with 500 μL of the incubation buffer for flow cytometry analysis. The percentage of the treated apoptotic and necrotic cells versus the untreated control cells was identified by the flow cytometry (Partec, GmbH Munster, Germany) method with Flomax software (version 2.4) at suitable excitation (488 nm) and emission wavelengths (518 nm) for Annexin-V detection and a band pass filter greater than 600 nm for propidium iodide (PI) detection according to the suggested protocol in the kit for FITC-PI detection.

Statistical analysis
--------------------

All the experiments were conducted in triplicate and the results were compared using one-way ANOVA for mean comparison of more than two groups with SPSSsoftware.[@b11-ijn-5-063] Results were reported as significant for *P* \< 0.05.

Results
=======

Chloride release
----------------

The rate of chloride ion release from the cisplatin in the presence of the dendrimers in aqueous media showed a higher (×2) and approximately the same as the free cisplatin in the absence of the dendrimers at 18 hrs after the beginning of the reaction ([Figure 2](#f2-ijn-5-063){ref-type="fig"}). Therefore, it was concluded that the rate of the reaction (chloride release) with cisplatin in the aqueous media containing the dendrimers was higher than in the aqueous media without the dendrimers. This may result from the contribution of the carboxylate ions together with the water molecules in displacing of the chloride ions from cisplatin.

Drug loading
------------

Almost the same amount of drug loading (\~6% weight of platinum/weight of the conjugates) was gained for each of the dendrimers irrespective of their generations and molar ratios ([Table 1](#t1-ijn-5-063){ref-type="table"}). This might result from the fact that the effect of the more functional groups in the G2 can be neutralized by its more associated steric repulsion in comparison with the G1.

*In vitro* release of platinum
------------------------------

The amount of platinum release from the two conjugates at differing pHs (pH 7.4 and pH 5.4 were selected in order to mimic the physiological media existing in the plasma and secondary lysosomes, respectively) showed both a time and concentration dependent behavior. According to the release amounts, the G2+Pt was a little more stable (less than 3%) than the G1+Pt. On the whole, the release rate in the acidic pH (5.4) was slightly greater and faster (about 2%) than the neutral pH (7.4) for both conjugates. This phenomenon can be explained due to the catalytic effect of the acidic conditions on the ease of displacement of water molecules with chloride or carboxylate ions inside the cisplatin cavity. This reduction in the release rate of cisplatin in neutral condition (pH 7.4) is very important in preserving a stable bond until reaching the target site (tumor) and therefore prevent unwanted and nonspecific toxicities resulting from out of place cisplatin release in the blood circulation. On the whole, the maximum released amount of platinum (approximately 8% of the total) was observed in the conjugate G1+Pt at pH 5.4 ([Figure 3](#f3-ijn-5-063){ref-type="fig"}).

Size and zeta potential distribution
------------------------------------

As can be observed from [Table 2](#t2-ijn-5-063){ref-type="table"}, when the conjugates were formed from the dendrimers, an increase in the size/poly dispersity and a decrease (negative charge) in the zeta potential were seen in the conjugates as contrasted with the dendrimers. The difference in the size was more marked (\~3×) in the G1+Pt conjugate, while the variance in the zeta potential distribution was more drastic (\~3×) in G2+Pt conjugate. This may result from the more negative groups being available at its surface. These phenomena can result from the cross-linking of the dendrimers with cisplatin which intercalates between two of the dendrimer molecules and also masks the negative charges (due to carboxylate ions) of the dendrimers for the reaction with cisplatin, respectively.[@b22-ijn-5-063]

FT-IR studies
-------------

In addition to typical peak characteristics of chemical structures of the dendrimers, FT-IR spectra of the conjugate products showed distinct alterations in the spectra ([Figure 4](#f4-ijn-5-063){ref-type="fig"}) indicating the conjugation at the dendrimer surfaces via carboxylate groups. For example, the marked increase in the \~31 cm^−1^ wavenumber of IR spectra of the G1 from 1577.81 cm^−1^ (assignable to asymmetric stretching of --COO--) to 1608.53 cm^−1^ for the G1+Pt may have resulted from the reaction of oxygen (as a strong base) of the carboxylate (--COO--) ion with platinum (as a weak Lewis acid). This type of bond polarizes, deshields the carbon atom of the --COO-- group, this induces a small positive charge on it, and consequently increases the possibility of the carbonyl group having a greater strength and wavenumber. Such an increment (about 25 cm^−1^) was also observed in the G2, a shift from 1593.17 cm^−1^, related to asymmetric stretching of the --COO-- group of the G2, to 1618.87 cm^−1^ for the G2+Pt. Moreover, the appearance a doublet bands near 3283 cm^−1^ and 3247 cm^−1^ for each of the G1+Pt and G2+Pt conjugates in comparison with the G1 and G2 dendrimers that is related to the stretching of the N-H groups of cisplatin.

*In vitro* cytotoxicity assay
-----------------------------

As can be seen from [Figure 5](#f5-ijn-5-063){ref-type="fig"}, the G2+Pt conjugate was more toxic than the parent cisplatin in all cell lines, times, and concentration range. The cytotoxic strength of some conjugates like G2+Pt based on IC~50~ calculation (the concentration which inhibits 50% growth against the maximum amount) with nonlinear regression (GraphPad,^®^ version 4) was 9 × greater in HT1080 (24 hrs) and CT26 (48 hrs) cell lines in comparison with free cisplatin while the conjugate G1+Pt showed a higher maximum toxicity of 3.7 × in CT26 cell line in comparison with the cisplatin after 48 hrs of incubation. In addition, the G1+Pt showed less toxicity in SKOV3 cell line increased to one third of free cisplatin after 48 hrs of incubation, while the same potency was observed for SKOV3 and free cisplatin after 24 hrs of incubation. The G1+Pt also showed less toxicity in CT26 cell line after 24 hrs of incubation. The IC~50~ values are displayed in [Figure 6](#f6-ijn-5-063){ref-type="fig"}.

Hemolysis assay
---------------

Based on the results gained from the hemoglobin release from the erythrocytes, only the G2+Pt conjugate at the concentration of 6 μg/mL showed a slightly more hemoglobin release about 1.5 × in comparison with the negative control (*P* \< 0.05). The rest of the conjugates did not show any statistical difference (*P* \> 0.05) against the negative control over the concentration range. Favourable hemocompatibility was found for these conjugates similar to cisplatin ([Figure 7](#f7-ijn-5-063){ref-type="fig"}).

Apoptosis-necrosis assay
------------------------

Apoptosis-necrosis assay was carried out at two moderately toxic concentrations (0.75 and 1.5 μg/mL) in order to determine and differentiate between the two cell death mechanisms induced by the conjugates and free cisplatin. These death mechanisms are considered crucial in determining the final treatment, eradication, and recurrence of the tumor cells.[@b23-ijn-5-063] From the results, a direct correlation between the concentration and cell death was observed for the derivatives and free cisplatin; ie, the higher the concentration the greater the degree of cell death. Greater toxicity was observed for the G2+Pt complex, and increased necrosis was also seen for this conjugate. Generally, the amount of apoptosis and necrosis, was higher nearly 8%, (\~2×) for the conjugates than those of cisplatin. The detailed results are presented in the [Figure 8](#f8-ijn-5-063){ref-type="fig"}.

Discussion
==========

In spite of using many kinds of polymers (traditional or nontraditional types) as drug carriers in the conjugation technique, only a small number of them have shown *in vitro* toxicity.[@b24-ijn-5-063] The ultimate cytotoxic actions of many types of these conjugates are met when they are used *in vivo* as an example the polymer-drug conjugates are very stable and not able to release the specified drug when they are inside the tumor cell environment for their final action.[@b25-ijn-5-063] In this study we have shown the synergistic toxic effect of the anionic linear-globular dendrimers (with terminal citric acid groups) conjugated to the surface of cisplatin. This action resulted in the more aqueous solubility of the conjugates as compared to the parent drug. The dendrimers themselves did not show any significant toxicity at the concentrations range used. These observations based on *in vitro* cytotoxicity (IC~50~ comparison) displayed that the G2+Pt conjugate showed a drastic increase in cytotoxicity in the sensitive cell line HT1080 (up to 8.4× and greater after 48 hrs) and CT26 (up to 9 × after 48 hrs) at all concentrations and exposure times used. Additionally continued toxicity was observed in these cell lines after 48 hrs of incubation. Such increased toxicity can be explained by a greater uptake of the conjugates as contrasted with the free cisplatin due to the citric acid content of the conjugates together with the greater demands of cancer cells for such energy sources during the time of incubation. The increased liberation of the drug may be attributed to lysosomal enzymes existing inside the cell which gradually breakdown the bond between cisplatin and the dendrimers. Similar reasons have been proposed for other polymer-drug conjugates thus far.[@b24-ijn-5-063] The G2+Pt showed greater toxicity \~2× as compared to the free cisplatin in the moderately resistant SKOV3 cell line. One of the possible resistance mechanisms of this cell line follows from the reduced uptake of cisplatin. [@b26-ijn-5-063] The G1+Pt conjugate showed an approximately a three fold increase in toxicity in the sensitive cell line HT1080. A similar behavior was observed for CT26 cell line only after 48 hrs of incubation (an increment of 3.7×) and much less toxicity was seen in this cell line after only 24 hr incubation time. This trend of increase in toxicity over time in the CT26 cell line can be explained by similar reasons to those mentioned above, ie, the gradual uptake and subsequent liberation of the drug due to action of enzymes inside the cell.

The G1+Pt displayed no toxicity in inherently resistant SKOV3 cell line as compared to free cisplatin. There was even a reduction (1/3 of the parent cisplatin) in toxicity observed for the G1+Pt conjugate after 48 hrs when compared to the 24 hrs incubation. A similar potency profile was observed for the G1+Pt conjugate to cisplatin at 24 hrs of incubation. This may suggest that hitherto unknown compensatory mechanisms could neutralize the synergistic effect of the conjugate during the time.

In general, the G2+Pt conjugate was more toxic than the G1+Pt conjugate. This might possibly be related to the higher citric acid content in the G2+Pt conjugate and consequently easier for the tumoric cells to access this for the supply of energy which is a prerequisite for growth.[@b27-ijn-5-063] The smaller and narrower the size distribution (ie, less aggregation behavior) of the G2+Pt conjugate may allow easier recognition and entry to the cell without requiring extra energy. In addition, this greater negative charge of the G2+Pt provides an increased number of sites being able to interact with the positively charged components of the cell membrane in comparison with the G1+Pt. This causes the G2+Pt conjugate to penetrate the cell more easily at an increased rate this could be another factor contributing to the increased cytotoxicity of the G2+Pt conjugate.

The hemolysis assay was used as a test for the interaction of compounds with the erythrocytes. Regarding the results, exactly the same hemolysis behavior was observed for all the conjugates except for the G2+Pt complex at the concentration of 6 μg/mL. This concentration showed an increment in the hemolysis only \~1.5 × against the negative control. Although relatively good hemocompatibility for the conjugates, complementary hemocompatibility was observed tests should be performed for better understanding of the hemotoxicity behaviors of these conjugates. With hemolysis results such as these there is little chance of clot formation which might continue in the blood circulation when using these conjugates *in vivo* eg, in the parenteral form.

Based on the results of the apoptosis-necrosis assays, both of the mechanisms are attributed to cell death, and a concentration dependency was observed for cisplatin and its derivatives. Also, greater toxicity (the percentage of apoptosis and necrosis \~1.5×) was observed for the conjugates as compared to the parent cisplatin. Overall, the mode of cell death is very important in cancer therapy as most of the resistances which are observed in cancer cell lines are due to apoptotic-related cell death.[@b28-ijn-5-063] The immunostimulatory impact of the products originating from necrotic cells may stimulate a macrophage-mediated antitumor response (contrary to apoptosis) and may produce an effective immune response by dendritic cells which must also be considered in the final therapeutic outcomes of antitumor drugs.[@b29-ijn-5-063],[@b30-ijn-5-063] Therefore, it seems possible that necrotic cell death could be more effective than apoptosis in cancer therapy. Certainly, it would be reasonable to consider the bi-lateral effects of necrosis in being an effective cancer treatment and the more accomapnied unwanted inflammatory reactions which may aggravate clinical tolerances to these drugs in patients during the treatment period. Thus, a balance must be made between the two processes of cell death. With respect to the greater potencies according to the more apoptosis-necrosis observed for the G2+Pt and the G1+Pt complexes compared to those of cisplatin, these compounds seem to be able to meet the necessary prerequisites for being good antitumor candidates against the cancer cell lines tested.

Conclusion
==========

Regarding the conjugates of cisplatin tested during this study and the *in vitro* results gained for their cytotoxicity, hemototoxicity, and nontoxicity of the dendrimers, it is hoped that these conjugates would be able to maintain the observed potency *in vivo* and retain the parent drug conjugated at the surface of the dendrimers in the physiologic plasma condition. This property can prohibit the unwanted release of free platinum before reaching the target site ie, tumor cells; to prevent the undesirable systemic toxicity, preclude excessive plasma protein binding with cisplatin, and ultimately exhibit a more repeatable, reproducible, and successful treatment in comparison with treating a patient with free cisplatin. Such drawbacks have been considered to be the main causes of the resistance mechanisms of cisplatin.[@b10-ijn-5-063] Furthermore, the conjugates, especially the G2+Pt conjugate, exhibited more cytotoxic potential in comparison with the parent drug in most of sensitive and resistant cell lines. Therefore, less of the conjugated parent drug would be required to obtain a similar therapeutic effect when compared with cisplatin treatment alone. It would therefore follow that such treatment could be attained with reduced systemic toxicity which is usually seen with this traditional antitumor agent. In brief, future *in vivo* studies will be able to clarify the potentiality of these entities in the cure of both sensitive and resistant cancerous cells.
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![Schematic diagrams of cisplatin (CDDP), the dendrimers G1, G2 and their possible reactions (generation of different conjugates) in aqueous media.](ijn-5-063f1){#f1-ijn-5-063}

![The comparative release of chloride ions from cisplatin (CDDP) alone and in reaction with the dendrimers G1 and G2.](ijn-5-063f2){#f2-ijn-5-063}

![*In vitro* release of platinum from the G1+Pt and G2+Pt conjugates at two different pHs.\
**Abbreviation:** h, hours.](ijn-5-063f3){#f3-ijn-5-063}

![FT-IR spectra of the dendrimers before and after the reaction with cisplatin (CDDP). IR: (**A**) G1, (**B**) G1+Pt, (**C**) G2, (**D**) G2+Pt.\
**Abbreviations:** FTIR, Fourier transform infrared; IR, infra-red.](ijn-5-063f4){#f4-ijn-5-063}

###### 

Viability of the different cancer cell lines according to the mitochondrial activity of the cells incubating with different kinds of Pt derivatives and free cisplatin (CDDP) after 24 and 48 hrs. (**A**) HT1080 cell line, (**B**) CT26 cell line, (c) SKOV3.
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![The IC~50~ of some of the conjugates and free cisplatin (CDDP) in different cancer cell lines at different times.\
**Abbreviation:** h, hours.](ijn-5-063f6){#f6-ijn-5-063}

![*In vitro* release of hemoglobin from human erythrocytes in contact with various concentrations of free cisplatin (CDDP) and Pt derivatives after 2 hrs of incubation.](ijn-5-063f7){#f7-ijn-5-063}

![Dot plot diagrams related to the amount of apoptosis-necrosis assays. Impact of the conjugates and free cisplatin (CDDP) at two concentrations on the percentage of apoptosis and necrosis. The data were analyzed with a version 2.4 of Flomax software. (**A**) negative control, (**B**) G1(0.75 μg/ml), (**C**) G1(1.5 μg/ml), (**D**) G2 (0.75 μg/ml), (**E**) G2 (1.5 μg/ml). (**F**) Platinum (0.75 μg/ml), (**G**) Platinum (1.5 μg/ml). Lower right: apoptotic cells, Upper right: necrotic and secondary apoptotic cells, Lower left: viable cells, Upper left: damaged cells.](ijn-5-063f8){#f8-ijn-5-063}

###### 

The weight percent of platinum in the conjugates at different ratios of the dendrimers to cisplatin

  Pt derivatives   Dedrimers: Pt (CDDP) Ratios   Pt content in wt % (mean ± SE) AAS method (flame)
  ---------------- ----------------------------- ---------------------------------------------------
  G1+Pt            1:2                           5 ± 0.21
  G1+Pt            1:3                           6 ± 0.33
  G2+Pt            1:2                           6 ± 0.21
  G2+Pt            1:3                           7 ± 0.15

###### 

Size and zeta potential distributions of the dendrimers and their related conjugates after reaction with cisplatin (CDDP)

  Types of the dendrimers and their derivatives   Size distribution, mean(nm) ± width    Zeta potential (mv) ± width
  ----------------------------------------------- -------------------------------------- ---------------------------------------------------------
  G1                                              225 ± 32.6 (100%)                      −17.6 ± 9.68 (100%)
  G1+Pt                                           710 ± 540 (94.5%); 4320 ± 873 (5.5%)   −16.4 ± 5.16 (100%)
  G2                                              85.1 ± 11 (100%)                       −67 ± 9.70 (78.5%); −41 ± 2.62 (8.1%); −7.4 ± 4.38 (8%)
  G2+Pt                                           141 ± 47.3 (100%)                      −20.9 ± 4.24 (85.2%); −6.58 ± 1.42 (14.8%)
